Stories from Penta ID Network

How the Penta experience changed the model of HIV care in Central America

Dr. Luis G Castaneda V, from El Salvador, shares his experience as attendee at Tr@inForPed course

It's a worthwhile journey

 Dr Pauline Amuge, from Uganda, speaks about her experience as a young investigator 

Severe infections and antimicrobial resistance

To know more about Penta’s activities on this field visit our “Severe infections and antimicrobial resistance webpage

AMR: a major threat to children's health

Video on antimicrobial resistance as a threat for children's health


Globally, many children and newborns with severe infections have virtually no new treatment options. Additionally,  there is a high level of resistance existing antibiotics, leading to an increased mortality rate for severe infections.

Collaboration with GARDP

Video "our studies in collaboration with GARDP"


In collaboration with GARDP, Penta has recently completed recruitment for an observational study (NeoOBS) designed to identify which bacteria causes sepsis in newborns, their resistance patterns and the most frequently used antibiotics to treat the infections. Part of NeoOBS programme is NeoFosfo, a trial aimed at identifying safety of fosfomycine in neonates.

Severe infections and AMR in Africa

Video on problem of infections and antimicrobial resistance in Africa


Antimicrobial resistance is responsible for half of all sepsis-related deaths in newborns in hospital. Babies which survive these type of infections face the possibility of neurodevelopment deficits. There is an urgent need to prioritized neonatal infection research in terms of diagnosis, prevention and treatment options for severe neonatal bacterial infections.

Penta's strategy on tackling AMR


Through observational and interventional clinical trials, Penta is committed to preventing multi-resistant severe infections in children and working to optimally manage those infections, improving mortality and clinical outcomes.

The history of Penta's research

Video on Penta's research history


Penta has used its years of experience and learning in the field of HIV, and taken this approach into the antimicrobials field. Penta’s approach is unique because Penta works both in infection prevention and treatment. It is through this that Penta can make progress in improving clinical outcomes and reducing children’s mortality worldwide.

The burden of neonatal sepsis in india

Ramesh Agarwal video


The burden of neonatal sepsis is particularly felt in India: incidence and fatality rate are very high if compared to high resource countries. Moreover, causative agents are often multidrug-resistant bugs. Policy makers, researchers, funders must work together to find the answers needed to improve clinical outcome of newborns in low-resource settings.

Penta's holistic view on antimicrobial resistance

Video: "penta's holistic view on antimicrobial resistance


Penta’s holistic approach to severe infections makes our strategy unique. Penta works both on mother and child, working to prevent mother-to-child transmission, but also on the identification of optimal treatment for infected babies .

Bringing antibiotics back to routine clinical care

Video "Bringing antibiotics back to routine clinical care"


Penta is committed to fight antimicrobial resistance, through a network of clinical sites working on observational trials in severe infections and antimicrobial resistance patterns. Observational studies allow the design and implementation of trials aiming to test routinely-used antibiotics as well as identify new antibiotics to optimally treat severe infections in children.

COVID-19: an HIV perspective

See COVID-19 through the eyes of young people living with HIV. A different perspective on the current pandemic, provided by young people dealing with a viral infection every day.